APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurometabolic Disorders

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neurometabolic Disorders Market Analysis and Forecast 2026-2032

19 December 2025206 pages

Choose your research edition.

Industry ResearchNeurometabolic Disorders Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurometabolic Disorders Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Neurometabolic Disorders Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurometabolic Disorders Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurometabolic Disorders Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Neurometabolic Disorders market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Neurometabolic Disorders is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neurometabolic Disorders is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neurometabolic Disorders is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neurometabolic Disorders is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Neurometabolic Disorders include Amicus, Amicus Therapeutics, Biomarin, Biosidus, Dong-A Socio Group, ExSAR Corporation, Genzyme, Greencross and Greenovation Biotech, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Neurometabolic Disorders, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neurometabolic Disorders, also provides the revenue of main regions and countries. Of the upcoming market potential for Neurometabolic Disorders, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neurometabolic Disorders revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neurometabolic Disorders market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Neurometabolic Disorders revenue, projected growth trends, production technology, application and end-user industry.

Neurometabolic Disorders Segment by Company

Amicus

Amicus Therapeutics

Biomarin

Biosidus

Dong-A Socio Group

ExSAR Corporation

Genzyme

Greencross

Greenovation Biotech

ISU Abxis

JCR Pharmaceuticals

Lixte Biotechnology

Neuraltus Pharmaceuticals

Pharming Group

Protalix

Protalix BioTherapeutics

Shire

UAB Proforma

Neurometabolic Disorders Segment by Type

Pompe Disease

Mucopolysaccharidosis VI

Gaucher’s Disease

Fabry Disease

Other

Neurometabolic Disorders Segment by Application

Oral

Parenteral

Neurometabolic Disorders Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurometabolic Disorders market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurometabolic Disorders and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurometabolic Disorders.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Neurometabolic Disorders in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Neurometabolic Disorders company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurometabolic Disorders revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neurometabolic Disorders Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Pompe Disease Major Player Table 3. Mucopolysaccharidosis VI Major Player Table 4. Gaucher’s Disease Major Player Table 5. Fabry Disease Major Player Table 6. Other Major Player Table 7. Global Neurometabolic Disorders Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Oral Major Player Table 9. Parenteral Major Player Table 10. Neurometabolic Disorders Industry Trends Table 11. Neurometabolic Disorders Industry Drivers Table 12. Neurometabolic Disorders Industry Opportunities and Challenges Table 13. Neurometabolic Disorders Industry Restraints Table 14. Global Neurometabolic Disorders Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Neurometabolic Disorders Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Neurometabolic Disorders Market Share by Region (2021-2026) Table 17. Global Neurometabolic Disorders Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Neurometabolic Disorders Market Share by Region (2027-2032) Table 19. Global Neurometabolic Disorders Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Neurometabolic Disorders Revenue Market Share by Players (2021-2026) Table 21. Global Neurometabolic Disorders Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Neurometabolic Disorders Key Players Headquarters & Area Served Table 23. Global Neurometabolic Disorders Players, Product Type & Application Table 24. Global Neurometabolic Disorders Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Neurometabolic Disorders by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Neurometabolic Disorders Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Neurometabolic Disorders Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Neurometabolic Disorders Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Neurometabolic Disorders Revenue Market Share by Type (2021-2026) Table 31. Global Neurometabolic Disorders Revenue Market Share by Type (2027-2032) Table 32. Global Neurometabolic Disorders Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Neurometabolic Disorders Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Neurometabolic Disorders Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Neurometabolic Disorders Revenue Market Share by Application (2021-2026) Table 36. Global Neurometabolic Disorders Revenue Market Share by Application (2027-2032) Table 37. Amicus Company Information Table 38. Amicus Business Overview Table 39. Amicus Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Amicus Neurometabolic Disorders Product Portfolio Table 41. Amicus Recent Development Table 42. Amicus Therapeutics Company Information Table 43. Amicus Therapeutics Business Overview Table 44. Amicus Therapeutics Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Amicus Therapeutics Neurometabolic Disorders Product Portfolio Table 46. Amicus Therapeutics Recent Development Table 47. Biomarin Company Information Table 48. Biomarin Business Overview Table 49. Biomarin Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Biomarin Neurometabolic Disorders Product Portfolio Table 51. Biomarin Recent Development Table 52. Biosidus Company Information Table 53. Biosidus Business Overview Table 54. Biosidus Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Biosidus Neurometabolic Disorders Product Portfolio Table 56. Biosidus Recent Development Table 57. Dong-A Socio Group Company Information Table 58. Dong-A Socio Group Business Overview Table 59. Dong-A Socio Group Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Dong-A Socio Group Neurometabolic Disorders Product Portfolio Table 61. Dong-A Socio Group Recent Development Table 62. ExSAR Corporation Company Information Table 63. ExSAR Corporation Business Overview Table 64. ExSAR Corporation Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. ExSAR Corporation Neurometabolic Disorders Product Portfolio Table 66. ExSAR Corporation Recent Development Table 67. Genzyme Company Information Table 68. Genzyme Business Overview Table 69. Genzyme Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Genzyme Neurometabolic Disorders Product Portfolio Table 71. Genzyme Recent Development Table 72. Greencross Company Information Table 73. Greencross Business Overview Table 74. Greencross Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Greencross Neurometabolic Disorders Product Portfolio Table 76. Greencross Recent Development Table 77. Greenovation Biotech Company Information Table 78. Greenovation Biotech Business Overview Table 79. Greenovation Biotech Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Greenovation Biotech Neurometabolic Disorders Product Portfolio Table 81. Greenovation Biotech Recent Development Table 82. ISU Abxis Company Information Table 83. ISU Abxis Business Overview Table 84. ISU Abxis Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. ISU Abxis Neurometabolic Disorders Product Portfolio Table 86. ISU Abxis Recent Development Table 87. JCR Pharmaceuticals Company Information Table 88. JCR Pharmaceuticals Business Overview Table 89. JCR Pharmaceuticals Neurometabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. JCR Pharmaceuticals Neurometabolic Disorders Product Portfolio Table 91. JCR Pharmaceuticals Recent Development Table 92. Lixte Biotechnology Company Information Table 93. Lixte Biotechnology Business Overview Table 94. Lixte Biotechnology Neurometabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Lixte Biotechnology Neurometabolic Disorders Product Portfolio Table 96. Lixte Biotechnology Recent Development Table 97. Neuraltus Pharmaceuticals Company Information Table 98. Neuraltus Pharmaceuticals Business Overview Table 99. Neuraltus Pharmaceuticals Neurometabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Neuraltus Pharmaceuticals Neurometabolic Disorders Product Portfolio Table 101. Neuraltus Pharmaceuticals Recent Development Table 102. Pharming Group Company Information Table 103. Pharming Group Business Overview Table 104. Pharming Group Neurometabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Pharming Group Neurometabolic Disorders Product Portfolio Table 106. Pharming Group Recent Development Table 107. Protalix Company Information Table 108. Protalix Business Overview Table 109. Protalix Neurometabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Protalix Neurometabolic Disorders Product Portfolio Table 111. Protalix Recent Development Table 112. Protalix BioTherapeutics Company Information Table 113. Protalix BioTherapeutics Business Overview Table 114. Protalix BioTherapeutics Neurometabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Protalix BioTherapeutics Neurometabolic Disorders Product Portfolio Table 116. Protalix BioTherapeutics Recent Development Table 117. Shire Company Information Table 118. Shire Business Overview Table 119. Shire Neurometabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Shire Neurometabolic Disorders Product Portfolio Table 121. Shire Recent Development Table 122. UAB Proforma Company Information Table 123. UAB Proforma Business Overview Table 124. UAB Proforma Neurometabolic Disorders Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. UAB Proforma Neurometabolic Disorders Product Portfolio Table 126. UAB Proforma Recent Development Table 127. North America Neurometabolic Disorders Revenue by Type (2021-2026) & (US$ Million) Table 128. North America Neurometabolic Disorders Revenue by Type (2027-2032) & (US$ Million) Table 129. North America Neurometabolic Disorders Revenue by Application (2021-2026) & (US$ Million) Table 130. North America Neurometabolic Disorders Revenue by Application (2027-2032) & (US$ Million) Table 131. North America Neurometabolic Disorders Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. North America Neurometabolic Disorders Revenue by Country (2021-2026) & (US$ Million) Table 133. North America Neurometabolic Disorders Revenue by Country (US$ Million) & (2027-2032) Table 134. Europe Neurometabolic Disorders Revenue by Type (2021-2026) & (US$ Million) Table 135. Europe Neurometabolic Disorders Revenue by Type (2027-2032) & (US$ Million) Table 136. Europe Neurometabolic Disorders Revenue by Application (2021-2026) & (US$ Million) Table 137. Europe Neurometabolic Disorders Revenue by Application (2027-2032) & (US$ Million) Table 138. Europe Neurometabolic Disorders Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Europe Neurometabolic Disorders Revenue by Country (2021-2026) & (US$ Million) Table 140. Europe Neurometabolic Disorders Revenue by Country (US$ Million) & (2027-2032) Table 141. China Neurometabolic Disorders Revenue by Type (2021-2026) & (US$ Million) Table 142. China Neurometabolic Disorders Revenue by Type (2027-2032) & (US$ Million) Table 143. China Neurometabolic Disorders Revenue by Application (2021-2026) & (US$ Million) Table 144. China Neurometabolic Disorders Revenue by Application (2027-2032) & (US$ Million) Table 145. Asia Neurometabolic Disorders Revenue by Type (2021-2026) & (US$ Million) Table 146. Asia Neurometabolic Disorders Revenue by Type (2027-2032) & (US$ Million) Table 147. Asia Neurometabolic Disorders Revenue by Application (2021-2026) & (US$ Million) Table 148. Asia Neurometabolic Disorders Revenue by Application (2027-2032) & (US$ Million) Table 149. Asia Neurometabolic Disorders Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 150. Asia Neurometabolic Disorders Revenue by Region (US$ Million) & (2021-2026) Table 151. Asia Neurometabolic Disorders Revenue by Region (US$ Million) & (2027-2032) Table 152. SAMEA Neurometabolic Disorders Revenue by Type (2021-2026) & (US$ Million) Table 153. SAMEA Neurometabolic Disorders Revenue by Type (2027-2032) & (US$ Million) Table 154. SAMEA Neurometabolic Disorders Revenue by Application (2021-2026) & (US$ Million) Table 155. SAMEA Neurometabolic Disorders Revenue by Application (2027-2032) & (US$ Million) Table 156. SAMEA Neurometabolic Disorders Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. SAMEA Neurometabolic Disorders Revenue by Country (2021-2026) & (US$ Million) Table 158. SAMEA Neurometabolic Disorders Revenue by Country (US$ Million) & (2027-2032) Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. Neurometabolic Disorders Image Figure 2. Global Neurometabolic Disorders Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurometabolic Disorders Market Size Share 2021 VS 2025 VS 2032 Figure 4. Pompe Disease Image Figure 5. Mucopolysaccharidosis VI Image Figure 6. Gaucher’s Disease Image Figure 7. Fabry Disease Image Figure 8. Other Image Figure 9. Global Neurometabolic Disorders Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Neurometabolic Disorders Market Size Share 2021 VS 2025 VS 2032 Figure 11. Oral Image Figure 12. Parenteral Image Figure 13. Global Neurometabolic Disorders Market Size (US$ Million) & (2021-2032) Figure 14. Global Neurometabolic Disorders Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Neurometabolic Disorders Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Neurometabolic Disorders Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Neurometabolic Disorders Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Neurometabolic Disorders Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Neurometabolic Disorders Revenue Market Share by Type (2021-2032) Figure 21. Global Neurometabolic Disorders Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Neurometabolic Disorders Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Neurometabolic Disorders Revenue Market Share by Application (2021-2032) Figure 24. North America Neurometabolic Disorders Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Neurometabolic Disorders Revenue Share by Type (2021-2032) Figure 26. North America Neurometabolic Disorders Revenue Share by Application (2021-2032) Figure 27. North America Neurometabolic Disorders Revenue Share by Country (2021-2032) Figure 28. United States Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Neurometabolic Disorders Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Neurometabolic Disorders Revenue Share by Type (2021-2032) Figure 33. Europe Neurometabolic Disorders Revenue Share by Application (2021-2032) Figure 34. Europe Neurometabolic Disorders Revenue Share by Country (2021-2032) Figure 35. Germany Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Neurometabolic Disorders Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Neurometabolic Disorders Revenue Share by Type (2021-2032) Figure 45. China Neurometabolic Disorders Revenue Share by Application (2021-2032) Figure 46. Asia Neurometabolic Disorders Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Neurometabolic Disorders Revenue Share by Type (2021-2032) Figure 48. Asia Neurometabolic Disorders Revenue Share by Application (2021-2032) Figure 49. Asia Neurometabolic Disorders Revenue Share by Region (2021-2032) Figure 50. Japan Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Neurometabolic Disorders Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Neurometabolic Disorders Revenue Share by Type (2021-2032) Figure 58. SAMEA Neurometabolic Disorders Revenue Share by Application (2021-2032) Figure 59. SAMEA Neurometabolic Disorders Revenue Share by Country (2021-2032) Figure 60. Brazil Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Neurometabolic Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Pompe Disease
  • Mucopolysaccharidosis VI
  • Gaucher’s Disease
  • Fabry Disease
  • Other
Applications
  • Oral
  • Parenteral
Companies covered
  • Amicus
  • Amicus Therapeutics
  • Biomarin
  • Biosidus
  • Dong-A Socio Group
  • ExSAR Corporation
  • Genzyme
  • Greencross
  • Greenovation Biotech
  • ISU Abxis
  • JCR Pharmaceuticals
  • Lixte Biotechnology
  • Neuraltus Pharmaceuticals
  • Pharming Group
  • Protalix
  • Protalix BioTherapeutics
  • Shire
  • UAB Proforma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neurometabolic Disorders Market by Type
  3. 1.2.1 Global Neurometabolic Disorders Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Pompe Disease
  5. 1.2.3 Mucopolysaccharidosis VI
  6. 1.2.4 Gaucher’s Disease
  7. 1.2.5 Fabry Disease
  8. 1.2.6 Other
  9. 1.3 Neurometabolic Disorders Market by Application
  10. 1.3.1 Global Neurometabolic Disorders Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Oral
  12. 1.3.3 Parenteral
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Neurometabolic Disorders Market Dynamics
  1. 2.1 Neurometabolic Disorders Industry Trends
  2. 2.2 Neurometabolic Disorders Industry Drivers
  3. 2.3 Neurometabolic Disorders Industry Opportunities and Challenges
  4. 2.4 Neurometabolic Disorders Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Neurometabolic Disorders Market Perspective (2021-2032)
  2. 3.2 Global Neurometabolic Disorders Growth Trends by Region
  3. 3.2.1 Global Neurometabolic Disorders Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neurometabolic Disorders Market Size by Region (2021-2026)
  5. 3.2.3 Global Neurometabolic Disorders Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Neurometabolic Disorders Revenue by Players
  2. 4.1.1 Global Neurometabolic Disorders Revenue by Players (2021-2026)
  3. 4.1.2 Global Neurometabolic Disorders Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Neurometabolic Disorders Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neurometabolic Disorders Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Neurometabolic Disorders Key Players Headquarters & Area Served
  7. 4.4 Global Neurometabolic Disorders Players, Product Type & Application
  8. 4.5 Global Neurometabolic Disorders Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Neurometabolic Disorders Market CR5 and HHI
  11. 4.6.3 2025 Neurometabolic Disorders Tier 1, Tier 2, and Tier 3
5 Neurometabolic Disorders Market Size by Type
  1. 5.1 Global Neurometabolic Disorders Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Neurometabolic Disorders Revenue by Type (2021-2032)
  3. 5.3 Global Neurometabolic Disorders Revenue Market Share by Type (2021-2032)
6 Neurometabolic Disorders Market Size by Application
  1. 6.1 Global Neurometabolic Disorders Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Neurometabolic Disorders Revenue by Application (2021-2032)
  3. 6.3 Global Neurometabolic Disorders Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Amicus
  2. 7.1.1 Amicus Company Information
  3. 7.1.2 Amicus Business Overview
  4. 7.1.3 Amicus Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Amicus Neurometabolic Disorders Product Portfolio
  6. 7.1.5 Amicus Recent Developments
  7. 7.2 Amicus Therapeutics
  8. 7.2.1 Amicus Therapeutics Company Information
  9. 7.2.2 Amicus Therapeutics Business Overview
  10. 7.2.3 Amicus Therapeutics Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Amicus Therapeutics Neurometabolic Disorders Product Portfolio
  12. 7.2.5 Amicus Therapeutics Recent Developments
  13. 7.3 Biomarin
  14. 7.3.1 Biomarin Company Information
  15. 7.3.2 Biomarin Business Overview
  16. 7.3.3 Biomarin Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Biomarin Neurometabolic Disorders Product Portfolio
  18. 7.3.5 Biomarin Recent Developments
  19. 7.4 Biosidus
  20. 7.4.1 Biosidus Company Information
  21. 7.4.2 Biosidus Business Overview
  22. 7.4.3 Biosidus Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Biosidus Neurometabolic Disorders Product Portfolio
  24. 7.4.5 Biosidus Recent Developments
  25. 7.5 Dong-A Socio Group
  26. 7.5.1 Dong-A Socio Group Company Information
  27. 7.5.2 Dong-A Socio Group Business Overview
  28. 7.5.3 Dong-A Socio Group Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Dong-A Socio Group Neurometabolic Disorders Product Portfolio
  30. 7.5.5 Dong-A Socio Group Recent Developments
  31. 7.6 ExSAR Corporation
  32. 7.6.1 ExSAR Corporation Company Information
  33. 7.6.2 ExSAR Corporation Business Overview
  34. 7.6.3 ExSAR Corporation Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  35. 7.6.4 ExSAR Corporation Neurometabolic Disorders Product Portfolio
  36. 7.6.5 ExSAR Corporation Recent Developments
  37. 7.7 Genzyme
  38. 7.7.1 Genzyme Company Information
  39. 7.7.2 Genzyme Business Overview
  40. 7.7.3 Genzyme Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Genzyme Neurometabolic Disorders Product Portfolio
  42. 7.7.5 Genzyme Recent Developments
  43. 7.8 Greencross
  44. 7.8.1 Greencross Company Information
  45. 7.8.2 Greencross Business Overview
  46. 7.8.3 Greencross Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Greencross Neurometabolic Disorders Product Portfolio
  48. 7.8.5 Greencross Recent Developments
  49. 7.9 Greenovation Biotech
  50. 7.9.1 Greenovation Biotech Company Information
  51. 7.9.2 Greenovation Biotech Business Overview
  52. 7.9.3 Greenovation Biotech Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Greenovation Biotech Neurometabolic Disorders Product Portfolio
  54. 7.9.5 Greenovation Biotech Recent Developments
  55. 7.10 ISU Abxis
  56. 7.10.1 ISU Abxis Company Information
  57. 7.10.2 ISU Abxis Business Overview
  58. 7.10.3 ISU Abxis Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  59. 7.10.4 ISU Abxis Neurometabolic Disorders Product Portfolio
  60. 7.10.5 ISU Abxis Recent Developments
  61. 7.11 JCR Pharmaceuticals
  62. 7.11.1 JCR Pharmaceuticals Company Information
  63. 7.11.2 JCR Pharmaceuticals Business Overview
  64. 7.11.3 JCR Pharmaceuticals Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  65. 7.11.4 JCR Pharmaceuticals Neurometabolic Disorders Product Portfolio
  66. 7.11.5 JCR Pharmaceuticals Recent Developments
  67. 7.12 Lixte Biotechnology
  68. 7.12.1 Lixte Biotechnology Company Information
  69. 7.12.2 Lixte Biotechnology Business Overview
  70. 7.12.3 Lixte Biotechnology Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Lixte Biotechnology Neurometabolic Disorders Product Portfolio
  72. 7.12.5 Lixte Biotechnology Recent Developments
  73. 7.13 Neuraltus Pharmaceuticals
  74. 7.13.1 Neuraltus Pharmaceuticals Company Information
  75. 7.13.2 Neuraltus Pharmaceuticals Business Overview
  76. 7.13.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Neuraltus Pharmaceuticals Neurometabolic Disorders Product Portfolio
  78. 7.13.5 Neuraltus Pharmaceuticals Recent Developments
  79. 7.14 Pharming Group
  80. 7.14.1 Pharming Group Company Information
  81. 7.14.2 Pharming Group Business Overview
  82. 7.14.3 Pharming Group Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Pharming Group Neurometabolic Disorders Product Portfolio
  84. 7.14.5 Pharming Group Recent Developments
  85. 7.15 Protalix
  86. 7.15.1 Protalix Company Information
  87. 7.15.2 Protalix Business Overview
  88. 7.15.3 Protalix Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Protalix Neurometabolic Disorders Product Portfolio
  90. 7.15.5 Protalix Recent Developments
  91. 7.16 Protalix BioTherapeutics
  92. 7.16.1 Protalix BioTherapeutics Company Information
  93. 7.16.2 Protalix BioTherapeutics Business Overview
  94. 7.16.3 Protalix BioTherapeutics Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Protalix BioTherapeutics Neurometabolic Disorders Product Portfolio
  96. 7.16.5 Protalix BioTherapeutics Recent Developments
  97. 7.17 Shire
  98. 7.17.1 Shire Company Information
  99. 7.17.2 Shire Business Overview
  100. 7.17.3 Shire Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Shire Neurometabolic Disorders Product Portfolio
  102. 7.17.5 Shire Recent Developments
  103. 7.18 UAB Proforma
  104. 7.18.1 UAB Proforma Company Information
  105. 7.18.2 UAB Proforma Business Overview
  106. 7.18.3 UAB Proforma Neurometabolic Disorders Revenue and Gross Margin (2021-2026)
  107. 7.18.4 UAB Proforma Neurometabolic Disorders Product Portfolio
  108. 7.18.5 UAB Proforma Recent Developments
8 North America
  1. 8.1 North America Neurometabolic Disorders Revenue (2021-2032)
  2. 8.2 North America Neurometabolic Disorders Revenue by Type (2021-2032)
  3. 8.2.1 North America Neurometabolic Disorders Revenue by Type (2021-2026)
  4. 8.2.2 North America Neurometabolic Disorders Revenue by Type (2027-2032)
  5. 8.3 North America Neurometabolic Disorders Revenue Share by Type (2021-2032)
  6. 8.4 North America Neurometabolic Disorders Revenue by Application (2021-2032)
  7. 8.4.1 North America Neurometabolic Disorders Revenue by Application (2021-2026)
  8. 8.4.2 North America Neurometabolic Disorders Revenue by Application (2027-2032)
  9. 8.5 North America Neurometabolic Disorders Revenue Share by Application (2021-2032)
  10. 8.6 North America Neurometabolic Disorders Revenue by Country
  11. 8.6.1 North America Neurometabolic Disorders Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Neurometabolic Disorders Revenue by Country (2021-2026)
  13. 8.6.3 North America Neurometabolic Disorders Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Neurometabolic Disorders Revenue (2021-2032)
  2. 9.2 Europe Neurometabolic Disorders Revenue by Type (2021-2032)
  3. 9.2.1 Europe Neurometabolic Disorders Revenue by Type (2021-2026)
  4. 9.2.2 Europe Neurometabolic Disorders Revenue by Type (2027-2032)
  5. 9.3 Europe Neurometabolic Disorders Revenue Share by Type (2021-2032)
  6. 9.4 Europe Neurometabolic Disorders Revenue by Application (2021-2032)
  7. 9.4.1 Europe Neurometabolic Disorders Revenue by Application (2021-2026)
  8. 9.4.2 Europe Neurometabolic Disorders Revenue by Application (2027-2032)
  9. 9.5 Europe Neurometabolic Disorders Revenue Share by Application (2021-2032)
  10. 9.6 Europe Neurometabolic Disorders Revenue by Country
  11. 9.6.1 Europe Neurometabolic Disorders Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Neurometabolic Disorders Revenue by Country (2021-2026)
  13. 9.6.3 Europe Neurometabolic Disorders Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Neurometabolic Disorders Revenue (2021-2032)
  2. 10.2 China Neurometabolic Disorders Revenue by Type (2021-2032)
  3. 10.2.1 China Neurometabolic Disorders Revenue by Type (2021-2026)
  4. 10.2.2 China Neurometabolic Disorders Revenue by Type (2027-2032)
  5. 10.3 China Neurometabolic Disorders Revenue Share by Type (2021-2032)
  6. 10.4 China Neurometabolic Disorders Revenue by Application (2021-2032)
  7. 10.4.1 China Neurometabolic Disorders Revenue by Application (2021-2026)
  8. 10.4.2 China Neurometabolic Disorders Revenue by Application (2027-2032)
  9. 10.5 China Neurometabolic Disorders Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neurometabolic Disorders Revenue (2021-2032)
  2. 11.2 Asia Neurometabolic Disorders Revenue by Type (2021-2032)
  3. 11.2.1 Asia Neurometabolic Disorders Revenue by Type (2021-2026)
  4. 11.2.2 Asia Neurometabolic Disorders Revenue by Type (2027-2032)
  5. 11.3 Asia Neurometabolic Disorders Revenue Share by Type (2021-2032)
  6. 11.4 Asia Neurometabolic Disorders Revenue by Application (2021-2032)
  7. 11.4.1 Asia Neurometabolic Disorders Revenue by Application (2021-2026)
  8. 11.4.2 Asia Neurometabolic Disorders Revenue by Application (2027-2032)
  9. 11.5 Asia Neurometabolic Disorders Revenue Share by Application (2021-2032)
  10. 11.6 Asia Neurometabolic Disorders Revenue by Country
  11. 11.6.1 Asia Neurometabolic Disorders Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Neurometabolic Disorders Revenue by Country (2021-2026)
  13. 11.6.3 Asia Neurometabolic Disorders Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neurometabolic Disorders Revenue (2021-2032)
  2. 12.2 SAMEA Neurometabolic Disorders Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Neurometabolic Disorders Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Neurometabolic Disorders Revenue by Type (2027-2032)
  5. 12.3 SAMEA Neurometabolic Disorders Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Neurometabolic Disorders Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Neurometabolic Disorders Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Neurometabolic Disorders Revenue by Application (2027-2032)
  9. 12.5 SAMEA Neurometabolic Disorders Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Neurometabolic Disorders Revenue by Country
  11. 12.6.1 SAMEA Neurometabolic Disorders Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Neurometabolic Disorders Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Neurometabolic Disorders Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst